Nephrology Medical News about renin angiotensin system;dual-versus mono-therapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Blocking the renin-angiotensin system: dual- versus mono-therapy
Expert Review of Cardiovascular Therapy , 06/12/09

Ravandi A et al. – A review of dual- vs mono-therapy for renin–angiotensin system (RAS) blockade reports that determination of whether dual therapy is beneficial in pts with diabetic renal failure is pending further study. Overall, pts receiving dual therapy, if clinically justified, must be monitored closely for potential adverse effects.

Methods

Review of dual- vs mono-therapy for RAS blockade
Summary of Valsartan in Acute Myocardial Infarction Trial (VALIANT), Ongoing Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events (ONTARGET), Candesartan in Heart Failure (CHARM), and Valsartan Heart Failure Trial (Val-HeFT) trials

Results

Target-organ damage is an effect of activated RAS partly due to hypertension
Blocking angiotensin-converting enzyme (ACE) attenuates RAS pathologic effects
ACE inhibition improves outcomes in prevention of acute myocardial infarction, lowering morbidity/mortality in congestive heart failure, and attenuates renal dysfunction
Angiotensin receptor blockers (ARBs) have similar efficacy to ACE inhibitors in reducing cardiovascular outcomes
Better overall inhibition of RAS by dual therapy may improve clinical outcomes
Combination therapy is beneficial in congestive heart failure or renal disease

Next >>
Use of Cardioprotective Medications in Kidney Transplant...